Jill Feldman recently shared a post by ASCO on X, adding:

“To say I am deeply honored to receive the ASCO Patient Advocate Award is an understatement! I wouldn’t be the advocate I am without the tireless and collaborative efforts of our community to advance research, elevate the patient voice & drive meaningful change. Thank you from the bottom of my heart.”

Quoting ASCO’s post:

“Along with Conquer Cancer, the ASCO Foundation, we congratulate the recipients of our 2024 Special Awards!”

Read further.
Source: Jill Feldman/X and ASCO/X

Jill Feldman is a lung cancer patient and advocate. She is the Co-Founder EGFR Resisters, an advocacy group of EGFR positive lung cancer patients who are resistant to targeted treatment. She is the Past President of the LUNGevity Foundation, Deputy Chair of IASLC’s patient advisory board and a member of The Chicago Institute of Translational Medicine’s patient advisory board. Jill is committed to understanding and promoting patient-centered research as a member of the programmatic panel for the Department of Defense Lung Cancer Research Program, as a planning committee member on IASLC’s North America Conference on Lung cancer and as a member of the the ECOG-ACRIN Research Group’s patient advocate committee and thoracic committee.